Imprime PGG (Imprime), an intravenously-administered, soluble β-glucan, has shown
compelling efficacy in multiple phase 2 clinical trials with tumor targeting or anti-angiogenic …

Vaccination with heat-killed Saccharomyces cerevisiae (HKY) protects against experimental
infection by pathogenic fungi of five genera. Here we tested whether purified …

Imprime PGG (Imprime) is in late-stage clinical development as a combinatorial agent with
several therapeutic modalities. Here we present pre-clinical mechanistic data supportive of …

Dectin-1A is a C-type lectin innate immunoreceptor that recognizes β-(1,3;1,6)-glucan, a
structural component of Candida species cell walls. β-Glucans can adopt solution structures …

We reported previously that yeast-derived whole glucan particles (WGPs), with or without
conjugation to BSA, used as a vaccine protected against systemic aspergillosis in mice. Here, …

Imprime PGG (Imprime), a soluble yeast 1,3/1,6 β-glucan, is being developed as a novel
cancer immunotherapy in conjunction with anti-tumor antibodies in several cancers. …

1703: A novel tumor vaccine platform: direct conjugation of antigens to the β glucan PAMP
Imprime PGG enhances antigen presentation and T cell priming | Cancer Research | …

Imprime PGG (Imprime), a soluble yeast 1,3/1,6 β-glucan, is being developed as a novel cancer
immunotherapy in combination with monoclonal antibody therapy. Randomized Phase 2 …

First Author: Karl V. CLEMONS, PhD Order of Authors: Karl V. CLEMONS, PhD Mary A.
Antonysamy, PhD Michael E. Danielson, PhD Kyle S. Michel, PhD Marife Martinez, BS Vicky …

Biothera is developing Imprime PGG® (Imprime PGG) for cancer that is synergistic with
multiple anti-tumor monoclonal antibodies, demonstrating the potential to improve patient …